Oncology Frontier:For patients in remission or stable after first-line treatment， when do we stop breast cancer treatment?

　　《肿瘤瞭望》：患者一线治疗后病情缓解或病情稳定，何时停止乳腺癌治疗？

　　Dr Gradishar: For patients with metastatic breast cancer who receive anti-HER2 therapy and who have demonstrated a response to that therapy， we may， over time， stop the chemotherapy part of the treatment but will typically continue the anti-HER2 therapy indefinitely. We would rescan the patient at regular intervals to determine whether they continue to benefit from the antibodies.

　　Gradishar医生：对于抗HER-2治疗起效的转移性乳腺癌，其“停止抗癌治疗”是持续进行的，先停止部分癌症疗法-化疗，但是通常继续抗HER-2治疗，治疗时间不确定，医生会定期检查患者以确认患者能否获益于所用抗HER-2药物。

　　Oncology Frontier: Are there any changes in the latest NCCN Guidelines for HER2-positive breast cancer?

　　《肿瘤瞭望》：在最新版NCCN指南中，HER-2阳性乳腺癌治疗推荐有哪些变化？

　　Dr Gradishar: The NCCN Guidelines are pretty clear that we recommend anti-HER2 therapy. We are less committed to saying it must be given to patients who have very tiny tumors but say it should be considered even in node-negative， <1cm tumors. That is clearly true if they are hormone receptor-negative. Patients with tumors >1cm in size should receive anti-HER2 therapy as their outcome will be improved as a result of that therapy as standard of care.

　　Gradishar医生：NCCN指南明确推荐，HER-2阳性乳腺癌采取抗HER-2治疗。但并非建议抗HER-2治疗肿瘤非常小的患者，只是建议淋巴结阴性、肿瘤<1 cm的患者也要考虑抗HER-2疗法，激素受体阴性的患者更要如此。肿瘤> 1cm的患者应以抗HER-2疗法作为标准治疗以改善治疗结果。